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1. Introduction 
Metastases to the brain is one of the most feared complication of systemic cancer and its 
incidence is rising for several reasons. The two most important reasons are the improvement 
in treatment, with a longer patient life; and the advance in diagnostic and imaging means 
Magnetic Resonance Image (MRI) and Computed Tomography (CT), Positron Emission 
Tomography [PET]) that have permitted to detect smaller lesions in asymptomatic patients. 
These improvement in radiology allows earlier diagnosis and result in better treatment 
management (Kamar et al., 2010, Rao et al, 2007, Patchell et al. 2003). Single metastases are 
detected in greater proportion. For example, in the case of ovarian tumors brain metastases 
are solitary in 43% of the cases (Pectasides et al. 2006). Single metastases appear 
approximately in one quarter of all patients with brain metastases (Rao et al. 2007). Norden 
et al. 2005 recently reported that breast, colon and renal cell carcinoma tend to produce 
single metastases, whereas melanoma and lung cancer have a greater tendency to produce 
multiple metastases. Single metastases can be treated surgically or by high precise 
radiotherapy modalities such as Gamma knife and StereoTactic Radiotherapy (SRT) or 
Conformal Radiotherapy (CRT). SRT was initially used for substituting surgical approach in 
patients with inaccessible tumor location or with comorbid medical conditions, now is used 
in many institutions as first approach, peculiarly from breast colon and renal carcinoma. 
Actually, many patients, refuse surgical approach so the use of SRT or CRT in combination 
with whole brain irradiation (WBRT) or SRT as a boosting method after WBRT is increasing. 
Associated to radiotherapy and chemotherapy we suggest and discuss the biological reasons 
for adding hyperthermia and glycolysis metabolic inhibitors with the aim to obtain a better 
control of brain metastases.  
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2. Epidemiology, pathology and prognosis of patients with brain metastasis 
Brain metastases occur in 20% to 40% of cancer patients. Posner and Chernik, from 1970 to 
1976 at the Memorial Sloan-Kettering Cancer Center, autopsied 3219 cancer patients. They 
found that 24% of these patients had intracranial metastases and the 20% had 
leptomeningeal metastases (Posner and Chernik 1978). Other studies reported similar 
percentage even if the methodology is slightly different (Baker et al. 1942, Chason et al 1963, 
Nussbaum 1996). In decreasing frequency, lung cancer, unknown primary, breast, 
melanoma, renal, and colon cancers are the most common tumors to metastasize to the brain 
(Pectasides et al. 2006, Norden et al. 2005, Posner and Chernic 1978, Chason et al 1963, 
Nussbaum et al. 1996).  
2.1 Localization of brain metastases 
Another important aspect is the precise localization of the metastases in the brain (Globus et 
al. 1942, Tom et al. 1946, Zimm et al. 1981, Tikhtman et al 1995). Approximately the 80% of 
metastases are localized in the cerebral hemisphere, 17% in the cerebellum and 3% in the 
brain stem (Tikhtman et al 1995). Delattre and contributors have also analyzed the 
localization of metastases in the specific regions of the cerebral hemisphere (Delattre et al. 
1988). They found that brain metastases involved the frontal area for 21%, the parietal and 
the temporoparietal-occipital for 19%. These authors have also outlined that metastasis 
located preferentially at the junction of gray and white matter. Hwang et al. recently 
reexamined the importance of the vascular border zone and the gray and white matter 
junction in the distribution of brain metastases and agreed with Delattre and contributors 
(Hwang et al. 1988). They found in 302 metastatic brain lesions studied, that gray and white 
matter junction was the preferred site for 64 % of the brain metastases and the vascular 
border zones were the site of predilection for the 62%. These results support the notion that 
metastatic emboli tend to lodge in an area of sudden reduction of vascular caliber 
(gray/white matter junction) and in the most distal vascular field area (Border zone) 
(Hwang et al. 1988).  
2.2 Shape of brain metastases 
Most metastases appear round well-demarcated lesions that displace rather than invade the 
surrounding brain parenchyma. The lesions can vary in size ranging from microscopic to 
masses of 1-4 centimeters in diameter. The histopathologic features are similar to that of 
tumor of origin.  
Microinvasion is present although the majority of metastatic lesions appear well demarcated 
and sometimes with reactive astrocytosis surrounding the metastatic area (Shaffrey et al. 
2004). A new vasculature can appear at peripheral zones and is part of the edema. In central 
areas, necrotic areas are present (Nathoo et al. 2005). Meningeal metastases diffuse into the 
subarachnoid space with accumulation around blood vessels (Shaffrey et al. 2004).  
2.3 Prognosis of brain metastases 
Untreated brain metastases have a dismal prognosis, generally no greater than 1-5 months. 
Gaspar et al. 2000, studying a RTOG (Radiation Therapy Oncology Group) data base, 
performed a Recursive – Partitioning Analysis [RPA] on 1200 patients. They identified the 
factors able to influence the prognosis of these patients (Gaspar et al. 2000, D’Ambrosio et al. 
2007). Among the several prognostic factors, Karnofsky Performance Status (KPS) has been 
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identified as the most important. The other important factors were: status of primary tumor, 
age and the presence or absence of systemic metastases. Stratifying the patients according 
these criteria they have been able to obtain the following prognostic factors. Patients with 
KPS = 70%, with age = 65 with controlled primary tumor and absence of systemic 
metastases had a median survival of 7.1 months, whereas the survival was reduced to 2.3 
months for patients with KPS < 70. The presence of uncontrolled tumor and systemic 
metastases even if with a KPS = 70% reduced the median survival to 4.2 months (Gaspar et 
al. 1997, 2000). The survival was not different between patients with undiagnosed primary 
lesion and thosewith diagnosed primary tumor (6 and 4.5 months, respectively; p = 0.097) as 
reported in a recent study by D’Ambrosio (D’Ambrosio et al. 2007).   
2.4 Brain metastases biology 
Researchers have gained insight into the mechanisms by which metastatic cells arise from 
certain primary tumors (i.e. breast, melanoma) and metastasize to brain. These findings 
have been obtained in a mouse model (Kang et al. 2004, Nicolson 1993, Beasley et al. 2011). 
These authors have outlined that metastases formation are not due to patterns of initial cell 
arrest, motility, or invasiveness, but rather to the ability of metastatic tumor cells to grow in 
that environment, this in agreement with the Paget hypothesis of seed and soil. In other 
words, the formation of metastasis requires the right cells with the compatible environment 
(Fidler 2002, 2010, Deichman 1998).  
Metastatic process is a high selective non-random process consisting in a series of linked 
sequential steps. In a heterogeneous population of primitive tumor cells only some are able 
to survive and to lodge at distant sites (Shaffrey et al. 2004). The outcome of cancer 
metastases depends on multiple interactions between metastatic cells and homeostatic 
mechanisms. Each metastatic step is selective and if the various steps are not completed, the 
metastatic process may fail. This is probably why only 0.01% of the cells that reach the 
circulation form a metastatic colony (Shaffrey et al. 2004, Kang et al 2004).  
For tutorial purpose we can divide the metastatic process to the brain in the following steps 
(Fidler 2010, Deichman 1998):  
A) process of selection among the heterogeneous tumor cells of origin into an aggressive 
and able to mobilize subpopulation; B) penetration of this selected subpopulation into the 
host circulation; C) localization into the microvasculature of the brain; D) crossing of Blood 
Brain Barrier (BBB); D) migration and growth in the brain structure.  
The process of selection (A) is the result of different pressures exerted by the tumor 
microenvironment and the genetic instability intrinsic to the tumor cells living in that 
environment. For different pressures we intend: tumor hypoxia, different metabolic 
advantageous tumor micro-area, immunologic pressure, presence or absence of an 
angiogenesis process. These different pressures can select among cells genetically unstable, 
cells able to survive in a different environment, to mobilize and to reach the blood stream 
(Deichman 1998). To gain access to the general circulation and to colonize to distant organs 
metastatic cells must invade tumor associated vasculature. The molecular mechanisms 
controlling the penetration of blood vessels are not completely understood (Beasley et al 
2011, Fidler 2002, 2010, Deichman 1998). Once these cells have reached the blood vessels, 
various mechanisms are needed to survive both the immune system and the shear stress. To 
avoid the identification the immune cells, metastatic cells shielded under an agglomerate of 
platelets and red blood cells (Deichman 1998)]. Other important mechanisms are the 
resistances by metastatic cells to the apoptotic effects of reactive oxygen radicals produced 
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by macrophages and neutrophils and the production of prostaglandins of E type (Fidler 
2002). Furthermore the adhesion of the platelets on the metastatic cells induces a 
hypercoagulable state that increases the metastatic potential. In fact this adhesion increases 
the resistance to both the immune system and the shear stress (Kehrli 1999).  
The most common metastatization to brain occurs by hematogenous route. One route is via 
the general circulation. In fact in the resting state, the brain receives 15% to 20% of the 
body's blood flow, thus making it likely that circulating tumor cells will reach the brain. The 
second, via the vertebral venous system (Batson’s plexus) which explains the absence of 
lung metastases found in certain patients with lung cancer. This spreading way is disputed 
and not confirmed by all authors (Deeken et al. 2007). 
Once metastatic cells have survived the circulatory stream, they may adhere to the 
endothelium, extravasate into the organ and then begin to proliferate in the new 
parenchyma. The arrest in the microcirculatory system is regulated by several factors, 
among them the multiple vascular adhesion molecules and the size of circulating emboli. 
Among adhesion molecules two families seem to be implicated: the selectins and the 
products of Immunoglobulin (Ig) genes and the integrins (Deeken et al. 2007). Integrins are 
major adhesion and signaling receptors that mediate cell migration and invasion (Shaffrey et 
al. 2004). In the case of human non small lung cancer (NSLC) the block of adhesion 
molecules integrin ǂ3ǃ1 has been demonstrated to significantly decrease the brain 
metastasis (Nathoo et al 2005).  
After reaching the brain capillaries, the metastatic cells must cross the BBB, degrade the 
brain Extracellular Matrix (ECM) and invade the brain parenchyma. This interaction is tight 
regulated by the paracrine and autocrine growth mechanisms present in the brain (Nicolson 
1993). BBB is constituted by brain endothelial cells associated with pericytes and astrocyte 
foot processes. Brain endothelial cells have continuous tight junction, no fenestrations and is 
highly selective in its permeability (Perides et al. 2006). In experimental melanoma the 
fibrinolytic system facilitates tumor cell migration across the BBB as demonstrated by 
Perides and his group (Perides et al. 2006). For metastasis to the brain from breast tumor, the 
cooperation between metastatic cells and astrocyte is of importance (Weil et al. 2005). 
To determine why certain tumors produce site-specific metastases to the brain, Fidler and 
collaborators studied cellsfrom K-175 melanoma syngeneic to C3H/HeN mice and the B16 
melanoma syngeneic to C57 Bl/6 mice (Fidler 1999, 2002, 2007). Regardless of the route of 
injection (internal carotid arteries-or directly into the cerebrum) K-175 produced 
melanocytic metastases in the brain parenchyma, whereas B16 cells produced lesions in the 
meninges and ventricles. These researches tried to understand which factors were 
responsible for the growth the melanoma cells in the specific areas (brain parenchyma, 
meninges). Some important aspects have been elucidated. For example B16 cells did not 
produce measurable gelatinase A activity whereas K- 175 cells did. The presence of 
gelatinase theoretically can facilitate cells extravasation and the growth into the 
parenchyma. However studies with hybrids of B16 and K-1735 able to produce gelatinase A, 
failed to grow into brain parenchyma. Fidler switched his research on the different growth 
factors present in the brain. He studied growth factors such as Epidermal Growth Factor 
(EGF), basic Fibroblast Growth Factor (bFGF), Platelet Derived Growth Factor (PDGF), 
however only Transforming Growth Factor-beta 2 (TGF-ǃ2 )showed a greater concentration 
in the brain and was able to inhibit the growth of B16 and B16/K-1735 hybrid cells 
explaining the incapacity of these hybrids in producing intraparenchymal brain metastases 
(Fidler 1999). 
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Whether the progressive growth of brain metastases depends on neovascularisation is also 
unclear. As outlined by Bucana: ”immunohistochemical and morphometric analyses show 
that the density of blood vessels within experimental metastases in the brains of nude mice, 
or within brain metastases derived from human lung cancer, is lower than in the adjacent, 
tumor-free brain parenchyma. However, blood vessels associated with brain metastases are 
dilated and contain many dividing endothelial cells. Immunohistochemical analysis also 
reveals that tumor cells located less than 100 micrometer from a blood vessel are viable, 
whereas more distant tumor cells undergo apoptosis. The blood-brain barrier is intact in and 
around experimental brain metastases smaller than 0.25 mm in diameter, but is leaky in 
larger metastases “(Bucana et al. 1999). Regarding melanoma other authors have found that 
neurotrophins (NTs) can promote brain metastases. NTs enhance the production of ECM 
degradation enzymes such as heparanases. Heparanases do not only degrade ECM but also 
the basement membrane of BBB Nathoo et al 2005, Menter et al 1994, Marchetti et al 2003, 
Denkins et al. 2004).  
The potential of angiogenesis in breast metastases has been further been studied. VEGF has 
been reported to increase the penetration of metastatic MDA-MB-231 breast carcinoma and 
to play a role in brain metastases dormancy in the absence of inhibitory antiangiogenic 
factors (Kim et al. 2004, Santarelli et al 2007, Palmieri et al. 2007, Yano et al,. 2000, Kaplan et 
al. 2005, Chen et al. 2007). Yano and collaborators however do not agree regarding the 
importance of VEGF on brain metastases and in an experimental mouse model using six 
different human cancer cell lines has reported that VEGF expression was necessary but not 
sufficient for the production of brain metastasis (Yano et al. 2000). 
Recently, the idea of premetastatic niche is leading the way (Kaplan et al 2006). Some 
authors support that the arrival of bone marrow-derived hematopoietic progenitors cells in 
distant sites represent early changes in the local environment (premetastatic niche) that 
dictates the pattern of metastatic spread and explains tumor dormancy (Kaplan et al. 
2005,2006). Santarelli et al. 2007, outline that the reactive monocytosis and activated 
microglia present in the premetastatic niche increase the local inflammatory response and 
can induce the growth of tumor cells transplanted to the brain. Furthermore these authors 
outline that it is plausible that the brain is able to generate the adequate environment in 
anticipation and preparation of the ensuing metastatic colonization (Santarelli et al. 2007). 
Other studies have evidenced new mechanistic insights regarding some kind of tumors such 
as breast cancer and melanoma. 
Her-2 receptor. Overexpression of Her-2 receptor in breast carcinoma seems not only 
correlated to a poor prognosis but also to an increased colonization to the brain as 
demonstrated by Palmieri et al. (2007). 
Metabolic factors. Regarding only breast carcinoma, Chen et al (2007) have evidenced by 
proteomic analysis, that brain- metastasizing cancer cells over expressed enzymes involved 
in aerobic glycolysis and tricarboxylic acid cycle (TCA) cycle. From this study the authors 
outline that breast cancer that colonize the brain are able to adapt to the energy metabolism 
of the brain or develop metabolism able to survive in that specific environment. 
Stat3. In melanoma, the activation and over expression of Stat3 (Signal Transducer and 
Activator of Transcription 3), as reported by Tong-Xin is associated to brain metastases and 
might be considered a new potential target in this clinical situation (Tong et al 2006). 
Metastasis suppressor genes. Recently seven Metastasis Suppressor Genes (MSGs) have 
been identified. These genes have no effect on the growth of primary tumors but have the 
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ability to suppress metastases in vivo. Proteins that regulate different functions such as 
adhesion, migration, growth and differentiation are coded by these MSGs. These genes have 
been described for breast carcinoma (Seraj et al. 2000), melanoma (Leone et al. 1991) and 
prostate cancer (Dong et al. 1995).  
Notwithstanding all these progresses the entire process of brain colonization remains 
actually poorly understood and better human and animal models are to be tried. It is our 
hypothesis that the peculiar metabolism of the normal brain with its high glucose uptake 
may explain the large incidence of metastases. 
3. Current methods of treatment of brain metastases 
The treatment of brain metastasis is multidisciplinary and different medical (surgeons, 
radiotherapists, chemotherapists) and non-medical figures (specialized nurses, health 
physicists, and radiotherapy technics) are interested. The clinical treatment consists in a 
combination of surgery, radiotherapy and chemotherapy. 
For describing the current therapies of brain metastases we have followed the suggestions of 
the “American College of Surgical oncology CNS Working Group” (2005) and some recent 
reviews on the argument (Shaffrey et al. 2004, Eichler A. F. and Loeffler J. S 2007, Ngguyen 
and De Angelis 2004). The criteria used by the American college of Surgical Oncology are 
the following: age, Karnofsky Index, presence or absence of non-Central Nervous System 
(CNS) metastasis. Using these criteria and the predictive study [RPA] of Gaspar et al. (1997, 
2000) it is possible to calculate the median survival. For patients falling in the RPA 1 with 
median survival = 7.1 months, an aggressive approach is suggested. It is out of doubt that 
the improvement in imaging techniques has changed the treatment options, and that the 
survival of patients with brain metastasis is dependent on the status of their systemic 
disease (Kamar et al. 2010, Rao et al. 2007, Patchell 2003, Eichler A. F. and Loeffler J. S 2007). 
3.1 Surgery 
Surgical approach has changed the survival and the quality of life of many patients. The 
most convincing evidence of this benefit is reported for Non-Small Lung Cancer (NSLC) 
patients with a single brain metastasis. Different authors have reported a 5-years survival 
ranging from 0% to 45% (Hankins et al. 1988, Wronski et al. 1995). As outlined by Nguyen 
and De Angelis (2004) this variation on survival is accounted by two factors: a) variation on 
treatment aggressiveness of primary lung tumor, b) variation on the incidence of systemic 
disease burden among those series. 
Surgical resection is generally followed by Whole - Brain Radiation Therapy (WBRT). WBRT 
has demonstrated palliation of neurologic symptoms and extension on survival (see studies 
of Patchell et al. 1990 and Vecht et al. 1993). Surgery for single metastases has shown benefit 
for melanoma (Buchsbaum et al. 2002), prostate cancer (McCutcheon et al. 1999), colorectal 
cancer (Hammoud et al. 1996), ovarian ( Cormio et al. 2003) and cervical cancer (Tajran et al. 
2003). 
Surgery for multiple brain metastases is a relatively new approach supported by the 
important retrospective study of University of Texas M.D. Anderson Cancer Center. In this 
study were treated 56 patients with no more than 3 metastases. No more than 3 craniotomies 
were performed and the group was divided in two subgroups according to the extension of 
the surgical resection. For one group [A] of 30 patients the complete resection was not 
possible, for a second group [B] of 26 patients the multiple metastases were completely 
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resected. In a third Group [C], 26 patients were resected for single metastasis and this group 
was used as control. From the comparison of the various subgroups the following results 
emerged: Group C and Group B obtained the same survival time and a multivariate analysis 
demonstrated that the only variables significantly affecting the survival were the groups of 
patients and the extent of the primary tumor (Bindal et al. 1993). The recurrence was similar 
in group B and C suggesting that an aggressive surgical approach may be useful. This 
approach has been confirmed by another study on 138 patients (Iwadate et al 2000). This 
study included other two variables: age and Karnofsky index. Age >60 years and Karnofsky 
< 70 and incomplete removal were significant factors. 
3.2 Radiation therapy 
Radiotherapy is the mainstay therapy of brain metastases. Currently there are three major 
categories of radio therapeutic treatments of brain metastasis: WBRT, radiosurgery, 
stereotactic radiotherapy. There are two options for radiosurgery: Gamma knife, Linac –
based radiosurgery.  
WBRT has been demonstrated by Patchell 1990 and Vecht 1993 to increase life survival in 
association with surgery. The WBRT is a palliative procedure which aim is to achieve life 
prolongation, local control and improvement in quality of life. WBRT has been also used 
prophylactically, aimed to treat malignancies having high brain metastasizing affinity, such 
as small cell lung carcinoma (SCLC), leukemia and lymphoma (Meert et al. 2001, Brown et 
al. 2005). The most frequently applied doses range from 20 Gy to 30 Gy in 5-10 sessions. 
Doses from 30 to 36 Gy are used as prophylaxis in the case of SLC and from 12-18 for 
hematologic diseases (Alexander et al. 1995, Brown et al. 2005). The combination of WBRT 
with radiosurgery will be discussed later. 
Radiosurgery is now possible because of the availability of CT and MRI and computer 
planning makes possible the delivery of high dose of radiation to a precise target tumor 
area. This delivering of precise high dose of radiation energy to a tumor is called 
radiosurgery. It can be achieved combining 3 elements: 1) stereotactic localization of 
metastatic lesion; 2) precise collimation of the radiation energy and 3) administration of the 
total dose coming from different points in space and intersected in a single target volume. 
The peculiarity of radiosurgery is the fall of dose at the target edges, this permit to 
concentrate the dose to the target tumor area sparing everything possible the healthy tissue 
surrounding the tumor (Lunsford et al. 1990). Two radiosurgical treatment facilities exist: 
Gamma Knife, Linac radiosurgery.  
Historically, LeKsell in Sweden was the first to apply radiosurgery. Initially low energy x-
rays (280 kV) were used and concentrated stereotactically to the intracranial target. The 
technique was first accepted with skepticism; however after the initial studies by Lunsford 
et al. (1990) (University of Pittsburgh), radiosurgery has gained a considerable acceptance. 
Lately in 1967, Leksell, in collaboration with Larsson, developed according to the same 
principle of radiosurgery the first cobalt - 60 gamma unit (Gamma Knife). 
The Gamma Knife contains 201 cobalt sources of gamma rays arrayed in a hemisphere 
within a shielded structure. A primary collimator, forces all the emitted sources to a 
common focal area, then a secondary collimator adapts this primary focal beam to sizes 
from 4 to 18 mm, through computer software, to target to the corresponding size of brain 
metastasis. In this case the limiting size of this device are brain metastases with a major 
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diameter = 18 mm or tumor volume ranged from 0.5 to 33 cm3 (Alexander et al. 1995, 
Lunsford et al. 1990). 
Following the same principle several authors (Betti et al. 1991, Colombo et al. 1985, Hartman 
et al. 1985, Giller and Berger 2005, Shoshan et al. 2005, Sperduto 2003, Valk and Dillon 1991) 
in the late 1980 developed LINAC based radiosurgical method. Linac radiosurgical 
treatment relies upon the following aspects: a) a collimated X-ray is directed stereotactically 
to the target area; b) the gentry of the linear accelerator rotates over the patient producing an 
arc of radiation oriented on the target. In this manner different arc or multiple non-coplanar 
intersecting arcs of radiation are used. Some important aspects of Linac therapeutic 
methodology are to be evidenced, they are: size, dose, toxicity.  
3.2.1 Size of target tumor volume  
Brain metastases have been considered ideal targets for radiosurgery and stereotactic 
radiotherapy due to their small spherical size, non-infiltrative borders, and location in non-
eloquent areas of the brain. In terms of stereotactic radiosurgery, the superiority of one 
energy source over another depends primarily on the dose distribution capabilities, which 
in turn depend on the target’s volume, location, and shape. For small lesions (= 5 cm3), the 
dose distributions produced by the gamma knife are essentially identical to those achievable 
with LINAC units. When the target lesion is non -spherical or of intermediate size ( =5 or = 
25 cm3), LINAC units may have an advantage over Gamma Knife units, due to their ability 
to treat larger lesions without requiring multiple isocenters (which makes treatment 
planning difficult), and the ability to shape the dose using collimated fields (Giller and 
Berger 2005). 
3.2.2 Dose fractionation  
Standard radiobiological principles suggest that fractionating radiation therapy (i.e., 
delivery in multiple sessions) will reduce both early and late toxicities to surrounding 
normal tissues. Radiotherapy can be delivered in a single session and is called radiosurgery, 
or in different sessions and is called: Stereotactic radiotherapy (SRT) or Conformal 
RadioTherapy (CRT) (Giller and Berger 2005, Shoshan et al. 2005, Sperduto 2003, Valk and 
Dillon 1991). 
3.2.3 Toxicity (radioprotection) 
Radiosurgery, notwithstanding its precision is not devoid of severe side effects on brain 
parenchyma, the worse being radionecrosis.CNS damage occurs in three different stages. 
The acute post radiation stage is usually well tolerated and consists in headache, nausea and 
somnolence. These symptoms are related to the cerebral edema and can be controlled with 
corticosteroids. A sub-acute stage caused by transient demyelization mediated damage to 
oligodendrocytes. This demyelization is clinically manifested by numbness, irritability, 
anorexia, somnolence and sometimes dysfunction of electric conduction. These symptoms 
occur approximately 10 weeks after cranial irradiation. Late effects (radionecrosis) become 
manifest from 6 to 9 months later and can evolve for a number of years following cranial 
irradiation. The process is associated with glia proliferation, mononuclear cell / astrocyte 
activation, and astrocyte secreted protein loss and cytokines production (Baker and Krochak 
1989, Michalowsky 1986). The endothelium damage is the principal target of irradiation, is 
irreversible and progressive and determines an increase in the blood brain permeability 
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(Valk and Dillon 1991). The leakier endothelium determines an increment in the quantity of 
fluid in the interstitium, an excessive production of free radicals due to the iron loss by red 
blood cells and an increased production of proinflammatory prostaglandins and cytokines 
(see Fig.1) (Michalowsky 1986, St Clair and Given 2003, Wong and Van der Kogel 2004). An 
interesting study by Kureshi et al. (1994) on frozen specimen obtained by patients with 
radionecrosis has shown that all specimen were infiltrated with both CD4+ and CD8+ cells 
and activated macrophages (CD11c+, HLA-DR+). Furthermore they analyzed a panel of 
cytokines and found that Tumor Necrosis Factor- ǂ (TNF-ǂ) and Interleukin-6 
immunoreactivity was prominent in majority of the specimen (75%) and were 
predominately produced by macrophages. TGF-[beta] astrocytic and macrophage 
immunoreactivity was present at moderate levels in all cases. Other authors have outlined 
that radiation injury is not only maintained by the inflammatory reaction elicited by 
radiation but is self maintained by the induction of apoptosis of endothelial cells (Wong and 
Van der Kogel 2004). These authors have also outlined the importance of hypoxia and VEGF 
production and of increased release of nitric oxide (NO) (Wong and Van der Kogel 2004). 
Belka et al. 2001, in agreement with us have outlined that radiation injury is the result of a 
complex alterations and that no single mechanism is responsible of the event. At least four 
factors contribute to central nervous system toxicity: (1) damage to vessel structures, (2) 
deletion of oligodendrocytes, (3) deletion of neural stem cells, (4) generalized alterations of 
cytokine expression (Kureshi et al. 1994). Actually no definitive therapies exist for 
radionecrosis (Valk and Dillon 1991, Belka et al 2001, Nieder et al 2007), however high 
dosage of corticosteroids, stem cell transplantation or erythropoietin (EPO) have been 
suggested. Pleiotropic functions of EPO on CNS have been recognized such as: inhibition of 
apoptosis, anti-inflammatory anti oxidative effects, prevention of glutamate-induced 
toxicity and stimulation of angiogenesis (Wong and Van der Kogel 2004). Other authors 
have proposed melatonin as radioprotective agent (Vijayalaxmi et al. 2004). Hyperbaric 
oxygen has been also proposed, however as outlined by Wong and Van der Kogel (2004), 
has not demonstrated a benefit. Since 1999, for brain metastases, a radioprotector formed by 
an association between bioflavonoids (silymarin) and omega three fatty acids has been 
suggested by an Italian group to decrease the risk ratio of developing brain necrosis and to 
improve significantly survival time (Gramaglia et al 1999). Omega 3 fatty acids have 
demonstrated to decrease the synthesis of proinflammatory prostaglandins (Fig.1) and 
cytokines, to have antitumoral activity and to change many tumor environmental 
parameters (Baronzio et al. 1994) whereas bioflavonoids have elicited protection of neuronal 
cells from oxidative stress and glutamate (Ishige et al 2001). A recent review on silymarin by 
Agarwaal et al. (2006) has outlined that this bioflavonoid has important anti-inflammatory 
and antiangiogenic activity. A vision of the various point of activity of these two natural 
drugs is illustrated in Fig.1. 
As previous described, Linac radiosurgery technology delivers high doses of ionizing 
radiation to small intracranial targets. SRT or CFRT requires: adequate a) patient 
immobilization, b) accurate three – dimension dose calculation TP (treatment planning); c) 
X-rays collimation.  
a. The patient immobilization. SRT is done using a frame fixed to patient’s skull using 
four pins. These pins are anchored into the periosteum and afford an excellent 
immobilization. The method is not devoid of side effects such infections and pain. 
Anesthetic is used during the procedure to control this last side effect. For treatment 
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that last several weeks the immobilization device should be reproducible and in this 
case an individual customized thermoplastic mould is built. 
 
 
Fig. 1. In this figure, the effects of Radiotherapy on Brain structure, the reactions produced 
and the targets of radioprotectors such as Sylimarin ** and omega 3 fatty acids (W-3) * are 
illustrated.  
b. Treatment Planning. After careful positioning the patient, is immobilized with 
thermoplastic moulds or with stereotactic frame undergoes to a contrast enhanced brain 
Computed Tomography (CT) or to a Brain Magnetic Resonance (MRI) scans with 2-5 
mm slice thickness and 2-5 mm separation. Once obtained the CT/MR data, these are 
processed using a computerized treatment planning. CT/MRI images are fused using 
image fusion software and the Gross Tumor Volume (GTV) is defined and contoured 
manually. In some departments an integration of images with metabolic information 
such as Single Photon Emission Computed Tomography (SPECT) is also used (Mongioj 
et al 1999).This permits sometimes to obtain more accurate tumor visualization. The 
fusion of images is obtained by commercial software (i.e. package SRS PLATO®) 
consisting of three principal algorithms: (1) a module dedicated to the localization of 
each tomographic section on stereotactic space; (2) a CT/MR dedicated module for the 
creation of regions of interest (ROIs) for each slice and (3) a 3D- visualization module. 
Once the GTV is obtained, a margin over these countered borders must be defined to 
take into account the possible microscopic extension of the tumor not evidenced on the 
CT/MR scans. These margins are generally 10-20 mm around the GTV obtaining the 
Planned Target Volume (PTV). After PTV determination, a new contour is done 
ensuring PTV coverage by 95% isodose line with the aim for obtaining uniform dose 
homogeneity.  
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c. Collimator. The major problem in radiosurgery is treating irregularly shaped lesions. 
The use of overlapping spherical treatments results in some shaping advantages but the 
increased time used to reproduce this technique determines a non-homogeneous dose 
deposition and an increase on side effects. Improved tumor dose homogeneity can be 
obtained using a field shaping device able to form an optimal field shape for each beam 
direction (Kurup et al 2007). To obtain the best dose distribution different devices have 
been set up (i.e. 3D line®, Radionics ®) (Gauer et al. 2008, urie et al. 2001). Generally, 
these collimator devices consist of two opposing banks tungsten leaves and allows 
shaping of a radiation field up to a size of 11 x 10 cm2 at the isocenter. Mechanical and 
dosimetric evaluations are performed to test the stability of the mechanical isocenter 
and to determine leaf leakage, penumbra width, and accuracy of leaf positions and 
uniformity of leaf speed. Several multileaf collimators are commercially available and 
differ from each other by many aspects such as: Leaf pairs, field size, leaf width, leaf 
transmission, maximum speed and total weight. As example, in table 1 we report some 
of the characteristics of 3D line® and that of Radionics ®. 
 
 Radionics 3Dline 
Leaf pairs 31 24 
Field size( cm2) 10x12 11x10 
Leaf Width (mm) 4 4.5 
Focused design Single Double 
Total weight (Kg) 35 35 
Maximum speed (cm/s) 2.5 1 
Table 1. Comparison of Some Characteristics of Radionics ® and 3Dline ® multileaf 
Collimator 
4. Current debates on the best treatment options 
An important question arises: is SRT efficacious as surgery in achieving local control (Rao et 
al. 2007)? As reviewed by Sperduto (2003), SRT is as good as or even better than surgical 
resection in term of local control. Another prospective study has addressed this question 
(Mucacevic et al. 2006). Mucacevic et al. 2006 found that local control was superior in SRT 
treated patients compared to surgery, and that SRT group had a greater improvement in 
quality of life even if a higher rate of distant brain failure was present. 
Another question is: can SRT be used only for multiple brain metastases? Previous studies 
suggested that use of radiosurgery for brain metastases should be limited to patients with 
three or fewer lesions (Gupta 2005, Andrews et al. 2004). A recent randomized trial, 
compared whole-brain radiation therapy (WBRT) plus radiosurgery boost to metastatic foci. 
This trial has demonstrated a significant advantage of radiosurgery boost over WBRT alone 
in terms of freedom from local failure, and that the result also present among patients with 
2, 3, or 4 metastases (Andrews et al. 2004). Survival also did not depend on number of 
metastases. The drawback of this technique is the risk of radiation necrosis. Chang et al. 
(2000) found that radionecrosis occurred in the 5.4% of patient treated and only 7 tumors 
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required subsequent surgical resection. Regarding toxicity by adding SRT + WBRT however, 
Aoyama et al. (2006) found no difference between the group treated with SRT alone or the 
group treated with SRT + WBRT. Furthermore they found that the patients in whom WBRT 
was omitted had a higher rate of failure in the brain (76%vs. 48%) and required salvage 
therapy more often for recurrent brain metastases. 
Study by Hidefumi et al. 2006, has clearly evidenced that WBRT associated to SRT improve 
the survival of patients with 1 to 4 brain metastases. Furthermore these authors outlined that 
intracranial relapse occurred more frequently in patients who did not receive WBRT. A 
recent study however indicate that SRT boost after WBRT for single brain metastases 
improves survival in select patients, whereas for patients up to four metastases the 
association improves local control not overall survival (Eichler and Loeffler 2007). Patchell et 
al. (1998) and Sneed et al. (2002) however disagree and from their retrospective and 
prospective data suggest that omitting WBRT does not result in shorter survival. They 
outline that the status of systemic disease is the predominant determinant of patient’s 
prognosis. To our opinion WBRT can omitted on selected patients with high risk of 
radionecrosis (increased accumulation of gadolinium in tumor area, neuro cognitive 
deterioration, persistence of headache and peritumoral edema) or if a close follow-up can be 
ensured to the patients treated with SRT. If patients do not show increased risk of 
radionecrosis, have a Karnofsky index > 70% and the systemic  
disease is minimal WBRT is however mandatory. 
4.1 Chemotherapy 
As outlined by Nguyen and De Angelis 2004, chemotherapy has a limited role in treating 
brain metastases and is used after failure of surgery and or radiation therapy. Many 
chemotherapy drugs do not cross the blood-brain barrier but can reach malignant tumors in 
the brain, presumably through a local breakdown in the blood-brain barrier. In some 
chemotherapy-sensitive tumors like, lymphoma, small cell lung cancer (SCLC) and breast 
cancer (Eichler and Loeffler 2007), chemotherapy can induce remissions, but its routine use 
is still under evaluation. But for most tumors, chemotherapy for brain metastases is 
ineffective, may be because of the existence of the BBB. In fact, many drugs do not cross 
easily BBB, and do not remain in the brain long enough or at high concentration to ensure 
adequate cancer killing effect (Tosoni et al. 2004). Drugs active on primary tumors may not 
be as active on metastases (Chang et al. 2007, Cavaliere and Shiff 2007). On the contrary 
other authors outline that brain metastases are as responsive as primary systemic cancer. 
This has been demonstrated by numerous phase II studies (Tosoni et al. 2004). 
Different chemotherapeutic regimens have been used for treating brain metastases from 
SCLC [52, 101]. Drugs have been used as single agent or combined to other drugs or 
associated with WBRT or SRT. The most active single drugs are cisplatinum (CCP), and 
temozolomide (TMZ) (Nguyen and De Angelis 2004). Cisplatinum alone has shown a 
response rate (RR) of 30% (Tosoni et al. 2004). A better response of 50% rate has been 
obtained combining to cisplatinum, etoposide, cyclophosphamide, methotrexate, and 5 
fluouracil (Tosoni et al. 2004). The association with WBRT was better in term of overall 
survival and in treatment response (57% vs 22%) compared to patients who had received 
only WBRT (Postmus et al. 2000). 
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Breast cancer is sensitive to chemotherapy (Cavaliere and Shiff 2007). Rosner et al (1986) 
have shown a 50% response rate among 100 women treated with different regimens. The 
most common agents are: cyclophosphamide, doxorubicin, 5-fluorouracil, methotrexate, and 
vincristine. All these agents do not cross BBB notwithstanding a response by metastatic foci 
have been obtained. This outlines that BBB is not so important and that the appropriate 
regimen and the chemosensitivity of the metastases are more important. Boogerd et al. 1992, 
reported a 59% RR, and according to Rosner et al. (1986), suggest that chemotherapeutics 
may cross BBB at a sufficient concentration to achieve a clinical effect. Another interesting 
and a standard drug on breast cancer is doxorubicin. Doxorubicin does not cross easily BBB 
however when encapsulated in liposomes its penetration can increase (Siegal et al. 1995). 
Caraglia et al. (2006) used liposomal doxorubicin and temozolomide (TMZ) in 19 patients 
with brain metastases. This association resulted in a RR of 37%; furthermore 8 patients had 
complete response and 2 a partial response. Temozolamide has limited activity against 
breast cancer so the majority of the response may be attributed to doxorubicin (Cavaliere 
and Shiff 2007). 
The incidence of metastases in breast cancer increases with the increase in HER2 
overexpression. HER2 is an 185KDa transmembrane tyrosine kinase with extensive 
homology to the epidermal growth factor receptor. Trastuzumab is a monoclonal antibody 
(MOaBs) now approved as a first line chemotherapy in patients with positivity for HER2 
receptors. After its introduction however an increased incidence in brain metastases has 
been noted. Retrospective studies documented an incidence between the 25% and the 40%, 
suggesting that HER-2 positive tumors have a biological predisposition to metastasize to 
brain (Lin and Winer 2007). The reasons for this increased incidence, as reported by Lin and 
Winer (2007), are multifactorial and include biological and treatment related factors. This 
last factor seems linked to the low penetration across BBB of Trastuzumab. Recently, to 
overcome this problem, Lapatinib has been suggested. Lapatinib has a dual inhibitor activity 
on epidermal growth factor and on HER2 and in preliminary has shown an objective 
response in two patients among 39 treated (Lin et al. 2006). Other studies with lapatinib and 
other HER2 inhibitors are currently been tested (Lin and Winer 2007). 
The incidence of brain metastases in melanoma is high and can reach the 43%. Melanoma is 
relatively chemoresistant. The various biological treatments such as interferon or 
interleukin-2 and chemotherapeutics (dacarbazine) have shown a limited activity. 
Temozolomide (TMZ) has demonstrated a relatively important response against brain 
metastases from melanoma. TMZ is a third generation alkylating agent that can be taken 
orally. Its small size and lipophilic properties, allows TMZ to cross easily BBB. CNS 
concentrations can reach 30% of the plasma concentrations. When it has reached the CNS, 
TMZ is converted to the active metabolite (MTIC). TMZ has been used as a single agent or 
combined with WBRT (Cavaliere and Shiff 2007). For example, in a phase II study on 151 
patients ( Agarwala et al. 2004), , 39 patients (26%) showed a stable disease. Other authors 
have reported similar results, futhermore the association of TMZ with WBRT resulted in a 
better overall survival compared to TMZ alone (9 months versus 5 months) (Hoffman et al. 
2006). 
4.2 Hyperthermia and metabolic inhibitors, the future? 
Multiple attempts have been made to improve the results of WBRT alone or combined with 
SRT/CFRT, by adding radiosensitizing agents. All the trials failed to demonstrate any 
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benefit either in local control or in survival (Eichler and Loeffler 2007). When brain 
metastases reach a critical mass > 1-2 mm3 (106 cells) and a distance from host nutritive 
vessel > of 100-200 μm develop area of hypoxia and angiogenesis. Hypoxia results in 
radioresistance (Wouters et al. 2007). Actually, no definitive clinical therapies exist for 
overcoming tumour hypoxia out of hyperthermia (HT) (Pontiggia et al. 1990, Baronzio et al. 
2006). HT is a treatment raising the temperature of tumor - loaded tissue to 40-43 degrees C. 
It is deprived of important side effects and has shown to enhance the effects of radiotherapy 
and to potentiate the efficacy of certain drugs, such as nitrosurea, cisplatinum, metothrexate 
(Baronzio et al. 2006, Dewey et al 1977). HT combined with radiation has been reported to 
yield higher complete and durable responses than radiation alone in superficial tumors. 
Despite difficulties in increasing human tumor temperatures, recent clinical trials have 
shown that a combination of hyperthermia with radiation is superior to radiation alone in 
controlling many human tumors (Dewey et al. 1977, Gabriele and Roca 2006). The increased 
effect seen by combining cytotoxic agents with hyperthermia is complex, but may be due to 
altered drug pharmacokinetics such as increased solubility (e.g. nitrosureas and alkylating 
agents), altered plasma protein binding (e.g. cisplatinum) and activation of enzymatic 
processes (e.g. anthracyclines) (Luk and Hulse 1980, Gerweek 1985). Hyperthermia does not 
usually cause marked increase in radiation side effects. Regarding brain, Seegenschmiedt et 
al. (1995), in their review affirmed that treatment toxicity to brain, is relatively low and long-
term side effects are similar to that observed to RT alone. Ikeda et al. (1994), studied the 
toxicity of radiofrequency interstitial HT in dog and found alteration of Blood Brain Barrier 
(BBB). Other authors outlined that the maximum tolerated heat dose to CNS lies in the range 
of 40-60 min at 42-42.5°C or 10-30 min at 43°C (Gerweek 1985). A recent review by Sharma 
and Hoopes (2003) has reported that HT specifically alters the mammalian CNS. The 
morphological alterations for temperature in the range 40°C to 42 °C for 4 hours has been 
demonstrated for the axons, the glial cells and the vascular endothelium. Sneed and Stea 
1995, demonstrated in a randomized study that HT has an acceptable toxicity, in fact no 
grade 5 toxicity was found outside 4 patients on 112 ( 3.5% ) with grade 2 and 7 (Sneed et al. 
1995). 
There are only a small number of studies on brain metastases with HT. In an interesting 
study reported by Pontiggia on 17 patients with lung cancer,the patients were treated with 
nitrosurea and capacitive HT for 60’. Sixteen patients out of 17 responded with clinical 
improvement and radiological regression of the disease. The survival time was in median 
12.7 months (Pontiggia et al. 1995). 
Hyperthermia is a useful adjunct to chemotherapy and radiotherapy; however, new 
therapeutic strategies easily applicable in many institutions are to be developed. 
The search for functional characteristics that allow cancer cells to spread to brain and 
development of new animal models will open new opportunities in target and drug 
discovery (Gril et al. 2010). Metabolic profiles of cells with metastatic propensity to brain 
may be one of these targets. In fact, studies by proteomics have demonstrated that breast 
cancer cells that metastasize to brain , have a unique protein profile consistent with 
increased expression of enzymes involved in glycolysis, tricarboxylic acid cycle, and 
oxidative phosphorylation pathways, permitting to these cells to have an enhanced 
proliferation and adaptation (Chen et al. 2007). Studies by Blasberg et al. (1985), using 14C-
deoxyglucose and quantitative autoradiography in metastatic walker 256 brain tumors 
confirm that glucose utilization is of primary importance in metastatic cells and that brain 
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metastases consume glucose in presence of a low oxygen tension, the so called aerobic 
glycolysis or “Warburg effect” (Warburg 1956). 
Palmieri et al. 2009 have confirmed the “Warburg effect” analyzing resected human brain 
metastases of breast cancer through real time PCR. They demonstrated an upregulation of 
hexokinase-2, an enzyme that mediates the first step of glucose metabolism, its upregulation 
is associated with a poor prognosis (Palmieri et al.2009). Hennipman et al. (1988) suggested 
an association of an increasing rate of enzymes implicated in glycolysis in breast cancer 
metastases and that their activities were higher in metastases compared to the primary 
tumors (Richardson et al. 2008). Another study on MCF10 model of mammary carcinoma by 
Richardson, confirms the major shift toward aerobic glycolysis (Gambhir et al. 2001). 
Increased glycolysis at metastatic site has been confirmed by [18F] 2-fluoro-2-deoxy-D-
glucose positron emission tomography (PET) (Richardson et al. 2008, Gambhir et al. 2001, 
Gillies et al. 2008, and Lee et al. 2008). 
Our group (Guais et al. 2010) has developed a drugs combination able to alter two different 
steps of tumor metabolism (pyruvate dehydrogenase and ATP citrate lyase). The first drug 
is ǂ-lipoic acid (ALA), which, as is the case for dichloroacetate, inhibits the enzyme Pyruvate 
Dehydrogenase Kinase-1 (PDHK1). Inhibition of PDHK1 can restore the activity of pyruvate 
dehydrogenase, thus possibly redirecting aerobic glycolysis to respiration and thus 
decreasing the amount of lactate produced. The second drug is hydroxycitrate (HCA), 
which inhibits ATP citrate lyase. The efficacy of this combination appears in animals to be 
similar to conventional chemotherapy (cisplatin or 5-FU), as it results in both significant 
tumor growth inhibition and enhanced survival (Schwartz et al. 2010). Similar results have 
been obtained in one case of pancreatic patient metastatic to liver (Guais et al. 2010). An 
unpublished result, of a patient with head and neck cancer with brain metastases treated 
with ALA and HCA and chemotherapy has shown a complete disappearance of brain 
metastases (personal communication). 
Immunohistochemistry studies on several specimens of primitive and metastatic human 
cancers, such as colon, breast, lung, ovarian and pancreas, have, also revealed an 
overexpression of hypoxia- inducible factor 1 (HIF) (Zhong et al. 1999). This overexpression 
supports two basic biological behavior of cancer and its metastases, an altered glucose 
transport and a limited diffusion of O2, glucose and nutrients (Liu et al. 2002). Hypoxic 
tumor cells become hypersensitized to glycolytic inhibitors (Liu et al. 2002) and to 
hyperthermia (Baronzio et al. 2006), reinforcing our hypotheses on metabolic treatment of 
metastatic cancer.  
5. Discussion and conclusions 
Patients with brain metastases have usually a short survival. Historical studies have 
demonstrated that with no treatments the survival is of the order of one - two months, due 
to systemic progression in sites other than brain. Although brain metastases incidence is 
increasing, there is no consensus for their treatment. Currently, treatment options include 
WBRT, surgery, chemotherapy and SRT/CRT. WBRT has the advantage of being easily and 
widely available and is able to extend survival to three to six months. In the case of solitary 
metastases, the addition of surgical resection to WBRT has doubled the survival, in the 
range of 10 - 12 months (Patchell et al. 1990, Heilbrun and Adler 2010). However, many 
patients have metastases in locations not amenable to surgical resection. STRT, for these 
patients has demonstrated in terms of survival and palliation to be a reliable clinical tool 
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(Brown and Pollock 2005). For larger lesions surgery could be considered when feasible in 
alternative to STRT even though in our opinion the SRT as first attempt could avoid the risk 
of seeding and partial resection. Surgery, in our institution, showed its major role in two 
different settings, i.e. for solitary brain disease with a controlled disease outside the brain 
and for resection of large necrotic masses, as result of previous STRT (mainly for lesions of 
more than 45 mm of diameter). A recent work has confirmed that previous surgical 
treatments have a negative impact on survival, suggesting that intervention must follows 
SRT (Vijayalaxmi et al 2004). As outlined by De Angelis (1994), another biological aspect, 
favoring the use SRT compared to WBRT, relies on that, approximately half of patients have 
single metastases and 20% of patients have only two metastatic lesions at the moment of 
their diagnosis. This aspect suggests that metastases to brain must be considered and treated 
as a local disease process. We suggest that the correct approach to patients bearing brain 
metastases should have to consider palliation as first intent. SRT, which reach this need 
faster than WBRT, is to be considered the treatment of choice mainly for patients bearing up 
to 3 lesions at first diagnosis, reserving WBRT as adjuvant to SRT and for palliation attempt 
to those with more than 3 lesions. Surgery must be used for patients without evident 
primary tumor and for necrotic lesions following aggressive radiotherapy. Furthermore, the 
altered glucose metabolism of metastases, suggests that the metabolic treatment is a 
promising line of research that could have significant therapeutic applications in a near 
future. 
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